SpyGlass Pharma, Inc. · BOATS:SGP

SpyGlass Pharma, Inc. financial statements

SpyGlass Pharma, Inc.'s income statement, balance sheet and cash flow, annual and quarterly, each figure dated and linked to the filing it was read from.

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023
Revenue000
Cost of revenue612.0K
Gross profit-612.0K
Research and development29.2M20.0M9.96M
Selling, general and administrative12.2M7.08M4.27M
Operating income-41.4M-27.1M-14.2M
Depreciation and amortization612.0K271.0K122.7K
EBITDA-40.8M-26.8M-14.1M
Income before tax-39.9M-29.2M-13.3M
Income tax00
Net income-39.9M-29.2M-13.3M
Earnings per share, basic-17.98-16.31-0.42
Earnings per share, diluted-17.98-16.31

Balance sheet

LineFY2025FY2024FY2023
Cash and equivalents96.4M16.3M15.8M
Short-term investments11.1M024.5M
Receivables431.0K
Current assets108.8M17.4M40.6M
Property, plant and equipment2.34M2.17M
Total assets115.9M23.3M41.1M
Accounts payable2.70M1.98M639.2K
Current liabilities8.58M7.79M1.59M
Total debt1.58M
Total liabilities10.2M11.2M74.1M
Shareholders' equity-98.8M-60.5M-33.0M
Shares outstanding2.20M2.20M31.9M

Cash flow

LineFY2025FY2024FY2023
Cash from operations-32.7M-22.0M-12.3M
Capital spending-789.0K-1.99M-216.5K
Free cash flow-33.5M-24.0M-12.5M
Cash from investing-11.8M22.3M
Cash from financing124.6M185.0K39.8M
Share buybacks-1.45M0
Change in cash80.1M419.0K7.01M